文献速递泌尿生殖与妇科肿瘤放疗

前列腺HDR近距离治疗单次19Gy与两次13.5Gy随机II期试验早期毒性与生活质量

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
PubMed 文献 · Radiother Oncol · 2016-11-04

随机II期试验纳入170例低中危前列腺癌患者,比较单次19Gy与两次13.5Gy HDR近距离治疗。中位随访20个月,两组耐受性均良好,但两次分割组在首年尿路症状和勃起功能障碍更常见。

要点

  • 单次19Gy与两次13.5Gy均耐受良好,无显著差异的2级泌尿毒性。
  • 两次分割组2级勃起功能障碍发生率更高(29% vs 11.5%,p=0.0249)。
  • 两组肠道和激素域生活质量无变化。

核心结论

  • 单次19Gy和两次13.5Gy均耐受良好,但两次分割组在首年泌尿症状和勃起功能障碍更常见。

研究设计与样本

  • 随机II期临床试验,170例低或中危前列腺癌患者,前列腺体积<60cc,未使用雄激素剥夺治疗。

主要发现

  • 中位随访20个月,两组急性期3个月内2级泌尿毒性发生率51%,之后31%,组间无显著差异。
  • 两组各发生1例3级急性(≤3个月)和晚期(>3个月)泌尿毒性,2级胃肠道毒性发生率不超过1%。
  • 两次分割组2级勃起功能障碍发生率29%,单次组11.5%(p=0.0249),且第一年IPSS评分更高。
  • 12个月时EPIC泌尿评分分别下降4.0和4.6,性功能评分分别下降8和15.9(p=0.035),肠道和激素域无变化。

临床怎么用

  • 对于低中危前列腺癌患者,单次19Gy和两次13.5Gy HDR近距离治疗均可作为安全选择。
  • 需关注两次分割方案在首年更高的泌尿症状和勃起功能障碍风险,个体化选择分割方案。

局限性

  • 随访时间较短(中位20个月),缺乏长期疗效和晚期毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Multi-fraction high dose-rate (HDR) brachytherapy as monotherapy is safe and effective for low and intermediate risk prostate cancer. Two or single fraction regimens have some radiobiological rationale. The purpose is to determine toxicity and effect on health related quality of life (HRQOL) of single fraction 19Gy or 13.5Gy×2. MATERIALS AND METHODS: Eligible patients had low or intermediate risk prostate cancer, prostate volume <60cc, and no androgen deprivation use. 170 patients were randomized to receive either a single 19Gy or two fractions of 13.5Gy 1week apart. HRQOL was measured using the Expanded Prostate Index Composite (EPIC), toxicity with Common Terminology for Adverse Events (CTCAE) v4.0 and urinary symptoms with the International Prostate Symptom Score (IPSS). RESULTS: Median follow-up is 20months. Grade 2 urinary toxicity occurred in 51% within the first 3months and in 31% thereafter with no significant difference between treatment arms. Ten patients (6%) developed urinary retention in the acute phase, although only 4 (2.4%) required a catheter for more than 48h. One Grade 3 acute (⩽3months) and late (>3months) urinary toxicity occurred. No more than 1% had any Grade 2 GI toxicity. The 2-fraction arm had a higher occurrence of grade 2 erectile dysfunction (29% vs. 11.5%, p=0.0249) and higher IPSS scores for the first year. Mean EPIC urinary scores at 12months decreased by 4.0 and 4.6, and sexual scores decreased by 8 and 15.9 (p=0.035) in the single and 2-fraction arms, respectively. No change occurred in the bowel or hormonal domains. CONCLUSIONS: Single 19Gy and 13.5Gy×2 are both well tolerated. During the first 12months, urinary symptoms and erectile dysfunction are more common in the 2-fraction arm.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Morton G, Chung HT, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radiother Oncol. 2016. PMID: 27823821. doi:10.1016/j.radonc.2016.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。